Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaySearch Laboratories ABCHIX:RAYBS -21.33%95 Earnings Yield (Joel Greenblatt) % is 3.67% as of Jun. 2026, which is 39% above its 10-year median of 2.64. GuruFocus rates CHIX:RAYBS with a GF Score™ of 95/100 and a GF Value™ of kr186.36 (Fairly Valued). The stock has 2 warning signs investors should review. Among 681 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 54.04% on this metric.
RaySearch Laboratories AB's Enterprise Value for the quarter that ended in Jun. 2026 was kr7,391 Mil.
RaySearch Laboratories AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was kr277 Mil. RaySearch Laboratories AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 3.67%.
The historical rank and industry rank for RaySearch Laboratories AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CHIX:RAYBs'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.94 Med: 2.64 Max: 4.86
Current: 4.45
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of RaySearch Laboratories AB was 4.86%. The lowest was -2.94%. And the median was 2.64%.
CHIX:RAYBs's Earnings Yield (Joel Greenblatt) % is ranked better than 54.04% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 3.71
vs CHIX:RAYBs: 4.45
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. RaySearch Laboratories AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
RaySearch Laboratories AB (CHIX:RAYBs) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
RaySearch Laboratories AB Earnings Yield (Joel Greenblatt) % Related Terms
RaySearch Laboratories AB Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for RaySearch Laboratories AB's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB Earnings Yield (Joel Greenblatt) % Chart
For the Health Information Services subindustry, RaySearch Laboratories AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Earnings Yield (Joel Greenblatt) % falls into.
RaySearch Laboratories AB Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
RaySearch Laboratories ABs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
RaySearch Laboratories AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr277 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 3.67% mean?
RaySearch Laboratories AB (CHIX:RAYBS) has a Earnings Yield (Joel Greenblatt) % of 3.67% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on RaySearch Laboratories AB and its competitors. This is 39% above median its historical median of 2.64. According to the industry distribution chart, RaySearch Laboratories AB ranks #313 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 46%.
Is RaySearch Laboratories AB's Earnings Yield (Joel Greenblatt) % too high?
RaySearch Laboratories AB's current Earnings Yield (Joel Greenblatt) % of 3.67% is 39% above median its 10-year median of 2.64. The Healthcare Providers & Services industry median Earnings Yield (Joel Greenblatt) % is 3.71. RaySearch Laboratories AB's value of 3.67% is 1.1% below this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #313 out of 681 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Earnings Yield (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #313 out of 681 companies for Earnings Yield (Joel Greenblatt) %. This puts RaySearch Laboratories AB in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.71. RaySearch Laboratories AB's value of 3.67% is 1.1% below this benchmark. While the company's 10-year median is 2.64 vs. the industry median of 3.71, RaySearch Laboratories AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.71, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Earnings Yield (Joel Greenblatt) % of 3.67% is 1.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Earnings Yield (Joel Greenblatt) % is 3.67%, which is 39% above median its own 10-year median of 2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Fairly Valued. The stock's GF Value™ is kr186.36, compared to a current price of kr184.65 — trading 0.9% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 3.67%, which is 39% above median its 10-year median of 2.64 and 1.1% below the Healthcare Providers & Services industry median of 3.71. RaySearch Laboratories AB's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Earnings Yield (Joel Greenblatt) % is 3.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be undervalued.
The current stock price of kr184.65 is trading 0.9% below its estimated GF Value™ of kr186.36.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for CHIX:RAYBS:
Earnings Yield (Joel Greenblatt) %: 3.67% (39% above median its 10-year median of 2.64)
GF Value™: kr186.36 vs. price of kr184.65 (0.9% below fair value)
Industry Position: 1.1% below the Healthcare Providers & Services median (#313 of 681)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
95GF Score
Get the complete analysis for CHIX:RAYBS
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
